Minimally invasive treatment of Raynaud phenomenon: the role of botulinum type A

Hand Clin. 2014 Feb;30(1):17-24. doi: 10.1016/j.hcl.2013.09.006.

Abstract

Although the mechanism is unknown, Btx-A injection may be an effective, localized, nonsurgical treatment option without addictive properties or systemic side effects for the treatment of ischemic digits. Clinical research supports the safety and efficacy of injection of Btx-A for the treatment of Raynaud phenomenon.

Keywords: Botulinum type A; Minimally invasive; Raynaud phenomenon; Treatment.

Publication types

  • Review

MeSH terms

  • Botulinum Toxins, Type A / pharmacology
  • Botulinum Toxins, Type A / therapeutic use*
  • Contraindications
  • Humans
  • Injections, Intralesional
  • Neuromuscular Agents / pharmacology
  • Neuromuscular Agents / therapeutic use*
  • Raynaud Disease / drug therapy*
  • Raynaud Disease / physiopathology
  • Treatment Outcome
  • Vasoconstriction / drug effects
  • Vasoconstriction / physiology

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A